Inari Medical Announces First Patient Enrolled in CLOUT Registry Using the ClotTriever Thrombectomy System

IRVINE, CALIFORNIA – September 27, 2018 — Inari Medical, Inc. announced today the enrollment of the first patient in the ClotTriever Outcomes Registry (“CLOUT”) using the ClotTriever® Thrombectomy System.

CLOUT is a 500-patient prospective, multicenter, single-arm registry to evaluate real world outcomes after treatment of patients with thrombosis in the deep veins of the lower extremity with ClotTriever.  Dr. William Marston, Chief of Vascular Surgery, University of North Carolina and Dr. Robert Beasley, Section Chief, Vascular and Interventional Radiology, Mount Sinai Medical Center, are Co-Principal Investigators.

“We are pleased to be the first site to enroll a patient in the CLOUT registry,” said Dr. Herman Kado, Medical Director of Cardiology, St. John Oakland Hospital.  “In our experience, the ClotTriever System consistently and efficiently removes iliofemoral clot, allowing us to complete treatment in a single session without the need for thrombolytic drugs or the consequent ICU stay.  We’re excited to help evaluate outcomes in a formal study.”

“ClotTriever is an important new tool for venous thrombus,” said Dr. Marston.  “The acute outcomes measures will allow us to evaluate the safety profile of ClotTriever as a single session non-thrombolytic option.  The two-year follow-up will allow us to determine if significant clot removal improves symptoms and outcomes over the longer term.”

“CLOUT reflects Inari’s commitment to VTE patients, to large volume clot removal from large veins, and to production of clinical data to help advance the understanding and treatment of the disease,” said Bill Hoffman, Inari’s Chief Executive Officer.  “We look forward to working with a dedicated group of physician investigators to execute this important study.”

 

About the ClotTriever Thrombectomy System

The ClotTriever system is designed to remove large clot volume from large veins via access sites as small as 6 mm.  The ClotTriever does not require use of thrombolytic drugs, which carry significant risk of bleeding and are contraindicated in many patients. The ClotTriever Thrombectomy System is 510(k) cleared for the non-surgical removal of thrombus (blood clots) from the peripheral vasculature.

 

About Inari Medical, Inc.
Inari Medical, Inc. is a privately held venture backed medical device company dedicated to the development of innovative catheter-based technologies for the treatment of venous thromboembolism (“VTE”).  Inari is focused on solutions that enable the safe removal of large clot volumes from big vessels without the use of thrombolytic drugs.  Inari has developed two novel mechanical thrombectomy technology platforms.  The ClotTriever System is 510(k) cleared for thrombectomy in the peripheral vessels.  The FlowTriever System is 510(k) cleared by the U.S. FDA for the treatment of pulmonary embolism.  Inari was founded in 2013 as a spin-out of Inceptus Medical, a medical device incubator. The company is backed by Gilde Healthcare (www.gildehealthcare.com), Versant Ventures (www.versantventures.com), U.S. Venture Partners (www.usvp.com), the founders and other private investors.  For more information, please visit www.inarimedical.com.  More information on the CLOUT Registry can be found at www.clinicaltrials.gov under NCT #03575364.

 

 

Contact
Tara Dunn, Vice President Clinical Affairs

tarad@inarimedical.com

 

# # #